Literature DB >> 29637239

[Cachexia and sarcopenia in chronic heart failure : Change in muscle strength and muscle structure].

N Ebner1, S von Haehling2.   

Abstract

Alterations to the body composition, i.e. the makeup of skeletal muscle, fat and bone density, are frequent in heart insufficiency. Their prevalence and clinical consequences are often underestimated. Cachexia is recognized as a complex multifactorial syndrome in chronic diseases that leads to weight loss. This point constitutes the essential differential criterion from sarcopenia. Cachexia is defined as a non-edematous weight loss of more than 5% within 12 months or less. Cachexia means weight loss, while sarcopenia means loss of muscle mass without weight loss because the functional muscle can be replaced by adipocytes. Sarcopenia is defined as a skeletal muscle mass index (SMMI) of at least 2 standard deviations below the mean value of a healthy young reference group between 20 and 30 years of the same sex and ethnic background. At the same time the walking speed is reduced to 1 m/s or the distance covered in a 6-min walk is <400m. The determination of loss of muscle mass should be carried out by whole body scanning, ideally with dual-energy x‑ray absorptiometry. A reliable and simple method for measurement of performance capability is the short physical performance battery (SPPB) test. The treatment of sarcopenia and cardiac cachexia in patients with heart insufficiency is still a great challenge. Power and endurance training, nutritional supplementation and drug therapy are possible therapeutic approaches; however, the study situation is unsatisfactory.

Entities:  

Keywords:  Absorptiometry, dual energy X‑ray; Dietary supplements; Exercise, physical; Muscle, skeletal; Walk test

Mesh:

Year:  2018        PMID: 29637239     DOI: 10.1007/s00108-018-0408-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  27 in total

Review 1.  Cachexia versus sarcopenia.

Authors:  Yves Rolland; Gabor Abellan van Kan; Sophie Gillette-Guyonnet; Bruno Vellas
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2011-01       Impact factor: 4.294

Review 2.  Functional and metabolic consequences of sarcopenia.

Authors:  W Evans
Journal:  J Nutr       Date:  1997-05       Impact factor: 4.798

3.  Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability.

Authors:  Ian Janssen; Steven B Heymsfield; Robert Ross
Journal:  J Am Geriatr Soc       Date:  2002-05       Impact factor: 5.562

Review 4.  Sarcopenia in older people.

Authors:  Solomon Yu; Kandiah Umapathysivam; Renuka Visvanathan
Journal:  Int J Evid Based Healthc       Date:  2014-12

Review 5.  Cardiac cachexia.

Authors:  Stefan D Anker; Wolfram Steinborn; Sabine Strassburg
Journal:  Ann Med       Date:  2004       Impact factor: 4.709

6.  Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.

Authors:  Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni
Journal:  Age Ageing       Date:  2010-04-13       Impact factor: 10.668

Review 7.  Epidemiology and consequences of sarcopenia.

Authors:  G Abellan van Kan
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

Review 8.  Signalling pathways that mediate skeletal muscle hypertrophy and atrophy.

Authors:  David J Glass
Journal:  Nat Cell Biol       Date:  2003-02       Impact factor: 28.824

Review 9.  The wasting continuum in heart failure: from sarcopenia to cachexia.

Authors:  Stephan von Haehling
Journal:  Proc Nutr Soc       Date:  2015-08-12       Impact factor: 6.297

10.  Unlocking the wasting enigma: Highlights from the 8th Cachexia Conference.

Authors:  Nicole Ebner; Stephan von Haehling
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-02-17       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.